Antibiotic activity of Leu-Lys rich model peptides
To develop novel antibiotic peptides useful as therapeutic drugs, short model peptides rich in Leu and Lys were designed by changing not only the net positive charge by Lys-deletion but also in the hydrophobic helix region by Leu-deletion from a peptide analogue of cecropin A (1-8)-magainin 2 (1-12)...
Gespeichert in:
| Veröffentlicht in: | Biotechnology letters 2003-08, Vol.25 (16), p.1305-1310 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1310 |
|---|---|
| container_issue | 16 |
| container_start_page | 1305 |
| container_title | Biotechnology letters |
| container_volume | 25 |
| creator | Park, Yoonkyung Lee, Dong Gun Hahm, Kyung-Soo |
| description | To develop novel antibiotic peptides useful as therapeutic drugs, short model peptides rich in Leu and Lys were designed by changing not only the net positive charge by Lys-deletion but also in the hydrophobic helix region by Leu-deletion from a peptide analogue of cecropin A (1-8)-magainin 2 (1-12) (CA-MA) known as P5. In particular, one peptide (P6), which was obtained by deleting Lys residues (positions 1, 3, 5, 9, 10, 13, 14) and Leu residues (positions 4, 7, 8, 11, 12, 15) and keeping Pro (position 6) and Trp (position 2), showed a strong antimicrobial and antitumor activity at 0.2-3.1 microM without hemolytic activity against human erythrocyte cells. Furthermore, P6 causes significant morphological alterations of the bacterial surfaces at 3.1 microM as shown by scanning electron microscopy. |
| doi_str_mv | 10.1023/A:1024995105208 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_75712450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75712450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-15b75878c69a6314714136c41b63d78f5487fcd49174aa368901daf761ca91733</originalsourceid><addsrcrecordid>eNqF0E1LxDAQBuAgiruunr1J8eCtmsnXJN6WxS8oeNFzSdMUs7Tb2qTC_nsLrhcvnl4YHoZ3hpBLoLdAGb9b388hjJFAJaP6iCxBIs8VojomSwoCcikMW5CzGLeUUoMUT8kChARBJS4JW-9SqEKfgsusS-ErpH3WN1nhp7zYx2wM7iPr-tq32eCHFGofz8lJY9voLw65Iu-PD2-b57x4fXrZrIvccaFTDrJCqVE7ZaziIHAuw5UTUCleo26k0Ni4WhhAYS1X2lCobYMKnJ1nnK_Izc_eYew_Jx9T2YXofNvane-nWKJEYELSfyFoIwXVMMPrP3DbT-NuPqLEuTNjWugZXR3QVHW-LocxdHbcl78_49_VCGot</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734822848</pqid></control><display><type>article</type><title>Antibiotic activity of Leu-Lys rich model peptides</title><source>MEDLINE</source><source>SpringerLink</source><creator>Park, Yoonkyung ; Lee, Dong Gun ; Hahm, Kyung-Soo</creator><creatorcontrib>Park, Yoonkyung ; Lee, Dong Gun ; Hahm, Kyung-Soo</creatorcontrib><description>To develop novel antibiotic peptides useful as therapeutic drugs, short model peptides rich in Leu and Lys were designed by changing not only the net positive charge by Lys-deletion but also in the hydrophobic helix region by Leu-deletion from a peptide analogue of cecropin A (1-8)-magainin 2 (1-12) (CA-MA) known as P5. In particular, one peptide (P6), which was obtained by deleting Lys residues (positions 1, 3, 5, 9, 10, 13, 14) and Leu residues (positions 4, 7, 8, 11, 12, 15) and keeping Pro (position 6) and Trp (position 2), showed a strong antimicrobial and antitumor activity at 0.2-3.1 microM without hemolytic activity against human erythrocyte cells. Furthermore, P6 causes significant morphological alterations of the bacterial surfaces at 3.1 microM as shown by scanning electron microscopy.</description><identifier>ISSN: 0141-5492</identifier><identifier>EISSN: 1573-6776</identifier><identifier>DOI: 10.1023/A:1024995105208</identifier><identifier>PMID: 14514057</identifier><language>eng</language><publisher>Netherlands: Springer Nature B.V</publisher><subject>Anti-Bacterial Agents - chemical synthesis ; Anti-Bacterial Agents - pharmacology ; Anti-Infective Agents - chemical synthesis ; Anti-Infective Agents - pharmacology ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; Bacteria - drug effects ; Bacteria - ultrastructure ; Cell Line, Tumor - drug effects ; Cell Survival - drug effects ; Dose-Response Relationship, Drug ; Drug Design ; Drug Screening Assays, Antitumor ; Erythrocytes ; Erythrocytes - drug effects ; Fungi - drug effects ; Hemolysis - drug effects ; Humans ; Leucine - chemistry ; Leucine - pharmacology ; Lysine - chemistry ; Lysine - pharmacology ; Microbial Sensitivity Tests ; Neoplasms - drug therapy ; Peptide Fragments ; Peptides ; Proteins ; Scanning electron microscopy</subject><ispartof>Biotechnology letters, 2003-08, Vol.25 (16), p.1305-1310</ispartof><rights>Kluwer Academic Publishers 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-15b75878c69a6314714136c41b63d78f5487fcd49174aa368901daf761ca91733</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14514057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Yoonkyung</creatorcontrib><creatorcontrib>Lee, Dong Gun</creatorcontrib><creatorcontrib>Hahm, Kyung-Soo</creatorcontrib><title>Antibiotic activity of Leu-Lys rich model peptides</title><title>Biotechnology letters</title><addtitle>Biotechnol Lett</addtitle><description>To develop novel antibiotic peptides useful as therapeutic drugs, short model peptides rich in Leu and Lys were designed by changing not only the net positive charge by Lys-deletion but also in the hydrophobic helix region by Leu-deletion from a peptide analogue of cecropin A (1-8)-magainin 2 (1-12) (CA-MA) known as P5. In particular, one peptide (P6), which was obtained by deleting Lys residues (positions 1, 3, 5, 9, 10, 13, 14) and Leu residues (positions 4, 7, 8, 11, 12, 15) and keeping Pro (position 6) and Trp (position 2), showed a strong antimicrobial and antitumor activity at 0.2-3.1 microM without hemolytic activity against human erythrocyte cells. Furthermore, P6 causes significant morphological alterations of the bacterial surfaces at 3.1 microM as shown by scanning electron microscopy.</description><subject>Anti-Bacterial Agents - chemical synthesis</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Infective Agents - chemical synthesis</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - ultrastructure</subject><subject>Cell Line, Tumor - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Erythrocytes</subject><subject>Erythrocytes - drug effects</subject><subject>Fungi - drug effects</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>Leucine - chemistry</subject><subject>Leucine - pharmacology</subject><subject>Lysine - chemistry</subject><subject>Lysine - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>Neoplasms - drug therapy</subject><subject>Peptide Fragments</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Scanning electron microscopy</subject><issn>0141-5492</issn><issn>1573-6776</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0E1LxDAQBuAgiruunr1J8eCtmsnXJN6WxS8oeNFzSdMUs7Tb2qTC_nsLrhcvnl4YHoZ3hpBLoLdAGb9b388hjJFAJaP6iCxBIs8VojomSwoCcikMW5CzGLeUUoMUT8kChARBJS4JW-9SqEKfgsusS-ErpH3WN1nhp7zYx2wM7iPr-tq32eCHFGofz8lJY9voLw65Iu-PD2-b57x4fXrZrIvccaFTDrJCqVE7ZaziIHAuw5UTUCleo26k0Ni4WhhAYS1X2lCobYMKnJ1nnK_Izc_eYew_Jx9T2YXofNvane-nWKJEYELSfyFoIwXVMMPrP3DbT-NuPqLEuTNjWugZXR3QVHW-LocxdHbcl78_49_VCGot</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>Park, Yoonkyung</creator><creator>Lee, Dong Gun</creator><creator>Hahm, Kyung-Soo</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QL</scope><scope>7QR</scope><scope>7T7</scope><scope>7TB</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>L7M</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>7QO</scope><scope>7X8</scope></search><sort><creationdate>20030801</creationdate><title>Antibiotic activity of Leu-Lys rich model peptides</title><author>Park, Yoonkyung ; Lee, Dong Gun ; Hahm, Kyung-Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-15b75878c69a6314714136c41b63d78f5487fcd49174aa368901daf761ca91733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Anti-Bacterial Agents - chemical synthesis</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Infective Agents - chemical synthesis</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - ultrastructure</topic><topic>Cell Line, Tumor - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Erythrocytes</topic><topic>Erythrocytes - drug effects</topic><topic>Fungi - drug effects</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>Leucine - chemistry</topic><topic>Leucine - pharmacology</topic><topic>Lysine - chemistry</topic><topic>Lysine - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>Neoplasms - drug therapy</topic><topic>Peptide Fragments</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Scanning electron microscopy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Yoonkyung</creatorcontrib><creatorcontrib>Lee, Dong Gun</creatorcontrib><creatorcontrib>Hahm, Kyung-Soo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biotechnology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Yoonkyung</au><au>Lee, Dong Gun</au><au>Hahm, Kyung-Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic activity of Leu-Lys rich model peptides</atitle><jtitle>Biotechnology letters</jtitle><addtitle>Biotechnol Lett</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>25</volume><issue>16</issue><spage>1305</spage><epage>1310</epage><pages>1305-1310</pages><issn>0141-5492</issn><eissn>1573-6776</eissn><abstract>To develop novel antibiotic peptides useful as therapeutic drugs, short model peptides rich in Leu and Lys were designed by changing not only the net positive charge by Lys-deletion but also in the hydrophobic helix region by Leu-deletion from a peptide analogue of cecropin A (1-8)-magainin 2 (1-12) (CA-MA) known as P5. In particular, one peptide (P6), which was obtained by deleting Lys residues (positions 1, 3, 5, 9, 10, 13, 14) and Leu residues (positions 4, 7, 8, 11, 12, 15) and keeping Pro (position 6) and Trp (position 2), showed a strong antimicrobial and antitumor activity at 0.2-3.1 microM without hemolytic activity against human erythrocyte cells. Furthermore, P6 causes significant morphological alterations of the bacterial surfaces at 3.1 microM as shown by scanning electron microscopy.</abstract><cop>Netherlands</cop><pub>Springer Nature B.V</pub><pmid>14514057</pmid><doi>10.1023/A:1024995105208</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-5492 |
| ispartof | Biotechnology letters, 2003-08, Vol.25 (16), p.1305-1310 |
| issn | 0141-5492 1573-6776 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75712450 |
| source | MEDLINE; SpringerLink |
| subjects | Anti-Bacterial Agents - chemical synthesis Anti-Bacterial Agents - pharmacology Anti-Infective Agents - chemical synthesis Anti-Infective Agents - pharmacology Antineoplastic Agents - chemical synthesis Antineoplastic Agents - pharmacology Bacteria - drug effects Bacteria - ultrastructure Cell Line, Tumor - drug effects Cell Survival - drug effects Dose-Response Relationship, Drug Drug Design Drug Screening Assays, Antitumor Erythrocytes Erythrocytes - drug effects Fungi - drug effects Hemolysis - drug effects Humans Leucine - chemistry Leucine - pharmacology Lysine - chemistry Lysine - pharmacology Microbial Sensitivity Tests Neoplasms - drug therapy Peptide Fragments Peptides Proteins Scanning electron microscopy |
| title | Antibiotic activity of Leu-Lys rich model peptides |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T16%3A27%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20activity%20of%20Leu-Lys%20rich%20model%20peptides&rft.jtitle=Biotechnology%20letters&rft.au=Park,%20Yoonkyung&rft.date=2003-08-01&rft.volume=25&rft.issue=16&rft.spage=1305&rft.epage=1310&rft.pages=1305-1310&rft.issn=0141-5492&rft.eissn=1573-6776&rft_id=info:doi/10.1023/A:1024995105208&rft_dat=%3Cproquest_pubme%3E75712450%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734822848&rft_id=info:pmid/14514057&rfr_iscdi=true |